ro compounded glp-1 launches insurance coverage checker Ro Launches GLP-1 Insurance Coverage

Gradual Tapering Approach Gradual tapering is one of the most recommended strategies for discontinuing GLP-1 medications

Medication ships only after PA resolves or cash-pay is confirmed

The lineup includes the Wegovy pill (oral semaglutide, FDA-approved December 2025, launched January 2026, the first FDA-approved oral GLP-1 for weight loss in adults), the Wegovy pen (injectable semaglutide 2.4 mg), Zepbound (tirzepatide via LillyDirect), and Ozempic (off-label for weight loss)

$350 to $550: both are viable

You can also track meals, calorie intake, and physical activity to better understand how your lifestyle adjustments are influencing your tapering process